Associated pathogenesis of bladder cancer and SARS-CoV-2 infection: a treatment strategy
- 24 September 2021
- journal article
- editorial
- Published by Springer Nature in VirusDisease
- Vol. 32 (4) , 613-615
Abstract
Coronavirus disease 19 (Covid-19) is a pandemic that affects every human on Earth. Mortality rates are greater in people with both cancer and Covid-19. In comparison, patients with non-Muscle-Invasive Bladder Cancer (NMIBC) had reduced susceptibility to moderate Covid-19 mortality. The treatment and clinical management of NMIBC are consistent with BCG-mediated intravesical adjuvant therapy as a protective function against tumors. BCG vaccination exhibits a non-specific protective role against respiratory infections. This non-specific effect of BCG is partially mediated by innate immune memory due to epigenetic changes in innate and adaptive immune system cells induced by the microbe. This editorial suggests that regularly test repurposed drugs include anti-cancer drugs till the proper antiviral drugs or vaccines will be developed.Keywords
This publication has 7 references indexed in Scilit:
- T cell responses in patients with COVID-19Nature Reviews Immunology, 2020
- Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital SystemCancer Discovery, 2020
- SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?Urologia Internationalis, 2020
- Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 OutbreakCancer Discovery, 2020
- Epigenetics and Trained ImmunityAntioxidants & Redox Signaling, 2018
- Targeting the IL-6/JAK/STAT3 signalling axis in cancerNature Reviews Clinical Oncology, 2018
- Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic reviewBMJ, 2016